<DOC>
	<DOC>NCT01169090</DOC>
	<brief_summary>The purpose of this study is to evaluate the safety and efficacy of a range of doses of SK-0403 in subjects with type 2 diabetes that are not adequately controlled on metformin alone.</brief_summary>
	<brief_title>A Study Comparing the Safety, Tolerance, and Efficacy of Various Doses of SK-0403 Versus Placebo and Sitagliptin 100 mg in Patients Not Well-Controlled on Metformin Therapy</brief_title>
	<detailed_description />
	<mesh_term>Metformin</mesh_term>
	<mesh_term>Sitagliptin Phosphate</mesh_term>
	<criteria>Male and female subjects with type 2 diabetes between 18 and 75 years of age, inclusive Screening HbA1c between 7.0% to 10.0% for metformin stable subjects, 6.5% to 9.0% for subjects on metformin and 1 other antidiabetic agent (excluding thiazolidinediones, insulin, or incretin therapies [DPP4 inhibitors and GLP1 analogues]), or 7.5% to 11.0% for subjects on no antidiabetic medication or, if taking metformin, not on a stable dose of 1500 mg/day or maximum tolerated dose. No antidiabetic medication other than metformin for 3 months prior to randomization. Fasting plasma glucose less than 270 mg/dL (15 mmol/L) at screening. Body mass index between 20 kg/m2 and 45 kg/m2 inclusive at screening. History of type 1 diabetes. Received treatment with insulin within 30 days of the screening visit or for more than 1 week within 3 months of the screening visit. Use of 3 or more oral antidiabetic medications at the time of the screening visit.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>August 2011</verification_date>
</DOC>